The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis
Abstract
Objective: The advent of tumor necrosis factor (TNF)–blocking drugs has provided rheumatologists with an effective, but highly expensive, treatment for the management of established rheumatoid arthritis (RA). Our aim was to explore preclinically the application of camelid anti‐TNF VHH proteins, which are single‐domain antigen binding (VHH) proteins homologous to human immunoglobulin V H domains, as TNF antagonists in a mouse model of RA. Methods: Llamas were immunized with human and mouse TNF, and antagonistic anti‐TNF VHH proteins were isolated and cloned for bacterial production. The resulting anti‐TNF VHH proteins were recombinantly linked to yield bivalent mouse and human TNF‐specific molecules. To increase the serum half‐life and targeting properties, an anti–serum albumin anti‐TNF VHH domain was incorporated into the bivalent molecules. The TNF‐neutralizing potential was analyzed in vitro. Mouse TNF‐specific molecules were tested in a therapeutic protocol in murine collagen‐induced arthritis (CIA). Disease progression was evaluated by clinical scoring and histologic evaluation. Targeting properties were evaluated by 99m Tc labeling and gamma camera imaging. Results: The bivalent molecules were up to 500 times more potent than the monovalent molecules. The antagonistic potency of the anti‐human TNF VHH proteins exceeded even that of the anti‐TNF antibodies infliximab and adalimumab that are used clinically in RA. Incorporation of binding affinity for albumin into the anti‐TNF VHH protein significantly prolonged its serum half‐life and promoted its targeting to inflamed joints in the murine CIA model of RA. This might explain the excellent therapeutic efficacy observed in vivo. Conclusion: These data suggest that because of the flexibility of their format, camelid anti‐TNF VHH proteins can be converted into potent therapeutic agents that can be produced and purified cost‐effectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Immunisation against heterologous type II collagen induces arthritis in mice
Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A., & Mosedale, B. (1980) · Nature · doi:10.1038/283666a0 · Cited by 1,025
Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
Arbabi Ghahroudi, M., Desmyter, A., Wyns, L., Hamers, R., & Muyldermans, S. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01062-4 · Cited by 768
Development of anti-TNF therapy for rheumatoid arthritis
Feldmann, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri802 · Cited by 673
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Single‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Chu, C. Q., Field, M., Feldmann, M., & Maini, R. N. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340908 · Cited by 578
Cited by
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Self-citationOrally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., et al. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.116 · Cited by 289
Self-citationA biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H., & Hackenberger, C. P. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708459 · Cited by 260
Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2)
Tillib, S. V., Ivanova, T. I., Vasilev, L. A., Rutovskaya, M. V., Saakyan, S. A., Gribova, I. Y., Tutykhina, I. L., Sedova, E. S., Lysenko, A. A., Shmarov, M. M., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2012.12.014 · Cited by 54
Advancements in Nanobody Epitope Prediction: A Comparative Study of AlphaFold2Multimer vs AlphaFold3
Eshak, F., & Goupil-Lamy, A. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01877 · Cited by 34
Metadata
- Authors
- Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., Hostens, J., Revets, H., Remaut, E., Elewaut, D., & Rottiers, P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-05-30
- Volume
- 54
- Issue
- 6
- Pages
- 1856-1866
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2079379157
- Cited by
- 303
- References
- 41
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.